Skip to Content

New Drug Approvals Archive - November 2004

See also: New Indications and Dosage Forms for November 2004

November 2004

TriCor (fenofibrate) Tablets

Date of Approval: November 5, 2004
Company: Abbott Laboratories
Treatment for: Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hypertriglyceridemia

TriCor (fenofibrate tablets) is a lipid regulating agent indicated for the treatment of hypercholesterolemia and hypertriglyceridemia.

Omacor (omega-3-acid ethyl esters) Capsules

Date of Approval: November 10, 2004
Company: Reliant Pharmaceuticals, Inc.
Treatment for: Hypertriglyceridemia

Omacor (omega-3 polyunsaturated fatty acids) is indicated as an adjunct to diet for the reduction of triglycerides in adult patients with very high triglyceride levels.

Tarceva (erlotinib) Tablets

Date of Approval: November 18, 2004
Company: OSI/Genentech
Treatment for: Non-Small Cell Lung Cancer, Pancreatic Cancer

Tarceva (erlotinib) is a kinase inhibitor indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

VESIcare (solifenacin) Tablets

Date of Approval: November 19, 2004
Company: Yamanouchi / GlaxoSmithKline
Treatment for: Overactive Bladder

VESIcare (solifenacin) is a muscarinic receptor antagonist treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Tysabri (natalizumab) Injection - formerly Antegren

Date of Approval: November 23, 2004
Company: Biogen Idec / Elan Corporation, plc
Treatment for: Multiple Sclerosis, Crohn's Disease -- Maintenance

Tysabri (natalizumab) is a recombinant humanized IgG4κ monoclonal antibody for the treatment of multiple sclerosis and Crohn's disease.

Combunox (ibuprofen and oxycodone hydrochloride) Tablets

Date of Approval: November 26, 2004
Company: Forest Laboratories, Inc.
Treatment for: Pain

Combunox (ibuprofen and oxycodone hydrochloride) is a nonsteroidal anti-inflammatory drug (NSAID) and opioid combination indicated for the short-term management of acute, moderate to severe pain.

Antara (fenofibrate) Capsules

Date of Approval: November 30, 2004
Company: Reliant Pharmaceuticals, Inc.
Treatment for: Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia

Antara (fenofibrate) is a lipid-lowering agent approved as adjunctive therapy to diet for the treatment of elevated levels of cholesterol and triglycerides.

Clindesse (clindamycin phosphate) Vaginal Cream

Date of Approval: November 30, 2004
Company: KV Pharmaceutical Company
Treatment for: Bacterial Vaginosis

Clindesse (clindamycin) Vaginal Cream is a single-dose topical antibiotic therapy indicated to treat bacterial vaginosis.

Captique (dermal filler) Injectable Gel

Date of Approval: November 12, 2004
Company: Inamed Corp / Genzyme Corp
Treatment for: Wrinkle Correction

Captique is a non-animal stabilized hyaluronic acid dermal filler indicated for the correction of moderate to severe facial wrinkles.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.